Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 3 |
| List of Tables | 4 | 1 |
| List of Figures | 4 | 1 |
| Introduction | 5 | 1 |
| Global Markets Direct Report Coverage | 5 | 1 |
| Bifunctional Epoxide Hydrolase 2 (Cytosolic Epoxide Hydrolase 2 or Epoxide Hydratase or Soluble Epoxide Hydrolase or Lipid Phosphate Phosphatase or EPHX2 or EC 3.3.2.10 or EC 3.1.3.76) Overview | 6 | 1 |
| Therapeutics Development | 7 | 3 |
| Bifunctional Epoxide Hydrolase 2 (Cytosolic Epoxide Hydrolase 2 or Epoxide Hydratase or Soluble Epoxide Hydrolase or Lipid Phosphate Phosphatase or EPHX2 or EC 3.3.2.10 or EC 3.1.3.76) Products under Development by Stage of Development | 7 | 1 |
| Bifunctional Epoxide Hydrolase 2 (Cytosolic Epoxide Hydrolase 2 or Epoxide Hydratase or Soluble Epoxide Hydrolase or Lipid Phosphate Phosphatase or EPHX2 or EC 3.3.2.10 or EC 3.1.3.76) Products under Development by Therapy Area | 8 | 1 |
| Bifunctional Epoxide Hydrolase 2 (Cytosolic Epoxide Hydrolase 2 or Epoxide Hydratase or Soluble Epoxide Hydrolase or Lipid Phosphate Phosphatase or EPHX2 or EC 3.3.2.10 or EC 3.1.3.76) Products under Development by Indication | 9 | 1 |
| Bifunctional Epoxide Hydrolase 2 (Cytosolic Epoxide Hydrolase 2 or Epoxide Hydratase or Soluble Epoxide Hydrolase or Lipid Phosphate Phosphatase or EPHX2 or EC 3.3.2.10 or EC 3.1.3.76) Pipeline Products Glance | 10 | 2 |
| Late Stage Products | 10 | 1 |
| Early Stage Products | 11 | 1 |
| Bifunctional Epoxide Hydrolase 2 (Cytosolic Epoxide Hydrolase 2 or Epoxide Hydratase or Soluble Epoxide Hydrolase or Lipid Phosphate Phosphatase or EPHX2 or EC 3.3.2.10 or EC 3.1.3.76) Products under Development by Companies | 12 | 2 |
| Bifunctional Epoxide Hydrolase 2 (Cytosolic Epoxide Hydrolase 2 or Epoxide Hydratase or Soluble Epoxide Hydrolase or Lipid Phosphate Phosphatase or EPHX2 or EC 3.3.2.10 or EC 3.1.3.76) Products under Development by Universities/Institutes | 14 | 2 |
| Bifunctional Epoxide Hydrolase 2 (Cytosolic Epoxide Hydrolase 2 or Epoxide Hydratase or Soluble Epoxide Hydrolase or Lipid Phosphate Phosphatase or EPHX2 or EC 3.3.2.10 or EC 3.1.3.76) Therapeutics Assessment | 16 | 5 |
| Assessment by Monotherapy/Combination Products | 16 | 1 |
| Assessment by Mechanism of Action | 17 | 1 |
| Assessment by Route of Administration | 18 | 2 |
| Assessment by Molecule Type | 20 | 1 |
| Bifunctional Epoxide Hydrolase 2 (Cytosolic Epoxide Hydrolase 2 or Epoxide Hydratase or Soluble Epoxide Hydrolase or Lipid Phosphate Phosphatase or EPHX2 or EC 3.3.2.10 or EC 3.1.3.76) Companies Involved in Therapeutics Development | 21 | 4 |
| GlaxoSmithKline Plc | 21 | 1 |
| Sphaera Pharma Pvt. Ltd. | 22 | 1 |
| Sumitomo Dainippon Pharma Co., Ltd. | 23 | 1 |
| Toray Industries, Inc. | 24 | 1 |
| Bifunctional Epoxide Hydrolase 2 (Cytosolic Epoxide Hydrolase 2 or Epoxide Hydratase or Soluble Epoxide Hydrolase or Lipid Phosphate Phosphatase or EPHX2 or EC 3.3.2.10 or EC 3.1.3.76) Drug Profiles | 25 | 11 |
| (diclofenac sodium + triclocarban) Drug Profile | 25 | 1 |
| EC-5026 Drug Profile | 26 | 1 |
| GSK-2256294 Drug Profile | 27 | 1 |
| RB-394 Drug Profile | 28 | 1 |
| Small Molecule to Inhibit Soluble Epoxide Hydrolase for Chronic Kidney Disease Drug Profile | 29 | 1 |
| Small Molecule to Inhibit Soluble Epoxide Hydrolase for Renal Protection Drug Profile | 30 | 1 |
| Small Molecule to Inhibit Soluble Epoxide Hydrolase for Sinusitis and Allergic Rhinitis Drug Profile | 31 | 1 |
| Small Molecules to Inhibit Cyclooxygenase 2 and Soluble Epoxide Hydrolase for Oncology Drug Profile | 32 | 1 |
| Small Molecules to Inhibit Soluble Epoxide Hydrolase for Inflammation and Pain Drug Profile | 33 | 1 |
| Small Molecules to Inhibit Soluble Epoxide Hydrolase for Myocardial Fibrosis Drug Profile | 34 | 1 |
| Small Molecules to Inhibit Soluble Epoxide Hydrolase for Pulmonary Arterial Hypertension Drug Profile | 35 | 1 |
| Bifunctional Epoxide Hydrolase 2 (Cytosolic Epoxide Hydrolase 2 or Epoxide Hydratase or Soluble Epoxide Hydrolase or Lipid Phosphate Phosphatase or EPHX2 or EC 3.3.2.10 or EC 3.1.3.76) Dormant Projects | 36 | 1 |
| Bifunctional Epoxide Hydrolase 2 (Cytosolic Epoxide Hydrolase 2 or Epoxide Hydratase or Soluble Epoxide Hydrolase or Lipid Phosphate Phosphatase or EPHX2 or EC 3.3.2.10 or EC 3.1.3.76) Featured News &Press Releases | 37 | 1 |
| Aug 19, 2013: Sphaera Pharma completes phase I trials for neuropathic pain drug | 37 | 1 |
| Appendix | 38 | 2 |
| Methodology | 38 | 1 |
| Coverage | 38 | 1 |
| Secondary Research | 38 | 1 |
| Primary Research | 38 | 1 |
| Expert Panel Validation | 38 | 1 |
| Contact Us | 38 | 1 |
| Disclaimer | 39 | 1 |